Nanovector Assembled from Natural Egg Yolk Lipids for Tumor-Targeted Delivery of Therapeutics

Authors:

Abstract
Nanomedicine uses nanotechnology-based strategies for precision tumor therapy, including passive and ligand-mediated active tumor targeting by nanocarriers. However, the possible biotoxicity of chemosynthetic nanovectors limits their clinical applications. A novel natural egg yolk lipid nanovector (EYLNs) was developed for effective loading and delivery of therapeutic agents. Lipids were extracted from egg yolks and reassembled into nano-sized particles. EYLNs stability, cellular uptake, toxicity, and delivery capacity for therapeutic agents were evaluated in vitro. Systemic toxicity and biodistribution of EYLNs were analyzed in normal mice, and the therapeutic effects of doxorubicin (Dox)-loaded EYLNs were evaluated in mouse breast cancer and hepatoma models. EYLNs had a particle size of ~40 nm and a surface zeta potential of −45 mV and were effectively internalized by tumor cells, without showing toxicity and side effects in vitro and in vivo. Importantly, their excellent permeability and retention effect significantly enhanced the distribution of EYLNs to tumor sites, and EYLN-Dox effectively inhibited the tumor growth in both mouse models. Targeted modification with folic acid further promoted vector-mediated drug distribution in tumors. This study demonstrates that lipids with specific proportions in the egg yolk can be used to construct natural drug vectors, providing a new strategy for nano-oncology research.
Funding Information
  • Natural Science Foundation of Jiangsu Province (BK20150421, BK20151287, BK20170455)
  • National Natural Science Foundation of China (81572877, 81772585, 81800149, 81972739)
  • Key Laboratory Projects of Huai?an, Jiangsu (HAP201606, HAP201804)

This publication has 57 references indexed in Scilit: